Skip to main content

Table 2 Outcomes of clinical trials of degraders presented at ASH 2024

From: Breakthroughs in treatment for hematological malignancies: latest updates on molecular glue, PROTACs and RNA degraders from ASH 2024

  1. BTK: Bruton’s Tyrosine Kinase; IKZF1/3: Ikaros Family Zinc Finger Proteins 1 and 3; IV: Intravenous/Intravenously; STAT3: Signal Transducer and Activator of Transcription 3
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us